• 1
    Karam R, Marcello S, Brooks RR, Corey AE, Moore A. Azimilide dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol 1998; 81: 40D46D.
  • 2
    Corey AE, Agnew JR, Valentine SN, et al. Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. J Clin Pharmacol 1999; 39: 12721276.
  • 3
    Procter and Gamble Pharmaceuticals. Data on File. 19831998.
  • 4
    Lam YWF, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997; 32: 3057.
  • 5
    Reidenberg MM. The biotransformation of drugs in renal failure. Am J Med 1977; 62: 482485.
  • 6
    Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000; 28: 13171320.
  • 7
    Corey A, Agnew J, Bao J, Bryson P, Comer P, Griffith S, Li J. Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride. J Clin Pharmacol 1997; 37: 946953.
  • 8
    Gibaldi M, Perrier D. Pharmacokinetics, 1st edn. New York: Marcel Dekker, Inc., 1975.
  • 9
    Jusko WJ. Guidelines for the collection and analysis of pharmacokinetic data. In Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 3rd edn, eds EvansWE, SchentagJJ, JuskoWJ. VancouverWA. Applied Therapeutics, Inc., 1992: 143.
  • 10
    Birkes D, Dodge Y. Alternative methods of regression. New York: John Wiley, 1993.
  • 11
    Corey A, Al-Khalidi H, Brezovic C, et al. Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. Biopharm Drug Dispos 1999; 20: 5968.
  • 12
    Huang SM, Green MD. Guidance for industry on pharmacokinetics in patients with impaired renal function – study design, data analysis, and impact on dosing and labeling. Fed Register 1998; 63: 2709427095.